How metabolism affects T cell function in cancer treatment
Metabolic impact on T cell-mediated cancer immunity and therapy
This study is looking at how T cells, which help our body fight cancer, can be made stronger and more effective, especially when they are in the tumor area and during different cancer treatments, to help improve immunotherapy options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10872207 on NIH RePORTER |
What this research studies
This research investigates the role of metabolism in T cell-mediated immunity against cancer. It aims to understand how T cells, which are crucial for fighting tumors, can be made more effective by exploring their behavior in the tumor microenvironment. The study will analyze the survival and functionality of these T cells, particularly focusing on their response to various cancer therapies, including checkpoint inhibitors and CAR-T cell treatments. By examining the molecular mechanisms that influence T cell performance, the research seeks to improve cancer immunotherapy strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who are undergoing or considering immunotherapy treatments.
Not a fit: Patients with non-cancerous conditions or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by enhancing T cell responses and improving patient outcomes.
How similar studies have performed: Other research has shown promising results in enhancing T cell function through metabolic interventions, indicating that this approach could be effective.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Zou, Weiping — University of Michigan at Ann Arbor
- Study coordinator: Zou, Weiping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.